Compare AbCellera Biologics Inc (ABCL) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Annaly Capital Management, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.95 (market cap $2.99B), while Annaly Capital Management, Inc. trades at $23.27 (market cap $17.44B). The key difference: Annaly Capital Management, Inc. is far larger — about 5.8× AbCellera Biologics Inc's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NLY | |
|---|---|---|
Market Cap | $2.99B | $17.44B |
Sector | Health | Financials |
52-Week High | $9.76 | $24.40 |
52-Week Low | $2.78 | $20.21 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
NLY trades at $23.28, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.59 and a high ROE of 20.66%. Recent quarterly earnings have consistently beaten estimates, and the company maintains a significant dividend yield. Analyst consensus is positive, with a $24.50 price target, supported by recent upgrades and institutional buying activity.
The outlook for NLY is favorable, driven by earnings growth and a high dividend yield, but risks include interest rate sensitivity and high leverage. The stock offers value and income appeal, yet investors should weigh the cyclical nature of the mortgage REIT sector against the strong analyst support and recent financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
